Flavopiridol for Advanced Soft Tissue Sarcoma
Author Information
Author(s): Morris Don G., Bramwell Vivien H. C., Turcotte Robert, Figueredo Alvaro T., Blackstein Martin E., Verma Shail, Matthews Sarah, Eisenhauer Elizabeth A.
Primary Institution: Tom Baker Cancer Centre, University of Calgary
Hypothesis
Can flavopiridol demonstrate activity and acceptable toxicity in patients with previously untreated advanced soft tissue sarcoma?
Conclusion
Flavopiridol was well tolerated, but no objective treatment responses were observed, indicating it may not be effective as a monotherapy for soft tissue sarcomas.
Supporting Evidence
- Eight patients (47%) exhibited stable disease after 2 cycles.
- Kaplan-Meier estimates for 3- and 6-month progression-free survival rates were 44% and 22%, respectively.
- Flavopiridol was administered at a dose of 50 mg/m2 IV over 1 hour daily for 3 days every 3 weeks.
Takeaway
This study tested a drug called flavopiridol in patients with a type of cancer called soft tissue sarcoma, but it didn't help them get better.
Methodology
Eighteen patients with advanced soft tissue sarcoma were treated with flavopiridol in a phase II nonrandomized, nonblinded clinical trial.
Limitations
The study was limited by the small sample size and the lack of objective responses.
Participant Demographics
The study included 18 patients, with a median age of 52 years, consisting of 6 females and 12 males.
Statistical Information
Confidence Interval
0.0–16.2%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website